Pregabalin Capsule
Product Images NDC 82804-188

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 82804-188). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-188-60 (Image 01)

Label for Pregabalin 150 mg capsules by Proficient Rx LP, containing 60 capsules. The label includes the drug's strength, capsule description (white cap/white body, size '2' gelatin capsules with imprints), product ID ZP018860, manufacturer HETERO Hetero Labs Limited in India, and storage instructions. Marked as Schedule C-V and RX only with barcode and multiple lot and expiration placeholders.*

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin at doses of 200 mg, 100 mg, and 25 mg taken three times a day, with a placebo group. Lines depict trends of patient improvement across increasing pain improvement percentages.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A Kaplan-Meier survival curve chart showing the estimated percentage of subjects without LTR over time in days, comparing Pregabalin and placebo groups. The solid line represents Pregabalin and the dashed line represents placebo, illustrating higher survival percentages with Pregabalin across the study duration.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph comparing the percent of subjects improved over time for Pregabalin versus Placebo. The X-axis represents the percent improvement from baseline to week 12, and the Y-axis shows the percent of subjects improved. The graph displays two curves: a solid line for Pregabalin and a dashed line for Placebo, with the Pregabalin curve consistently higher.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line chart comparing the percentage of subjects improved over time between Pregabalin and Placebo groups. The x-axis represents percent improved from baseline to week 16 BOCF, while the y-axis shows the percent of subjects improved, ranging from 0 to 100%. Pregabalin is represented by a solid line and Placebo by a dotted line.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph showing the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. The graph compares Pregabalin 100 mg three times a day with placebo, illustrating the distribution of patient responses for both treatments.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares four groups: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo, depicting varying effectiveness levels over the improvement range.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph depicting the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing higher patient improvement with Pregabalin doses compared to placebo.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line chart showing the percent improvement in pain from baseline on the x-axis against the percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating differences in patient pain improvement percentages between treatments.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar chart comparing responder rates (%) across different treatment groups in two studies labeled Study E1 and Study E3. Study E1 groups include Placebo, 150 mg/day, 300 mg/day, and 600 mg/day doses, while Study E3 groups include Placebo, 600 mg/day, and 710 mg/day doses. The chart shows increased responder rates with higher doses compared to placebo in both studies.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A line graph depicting median percentage change in seizure reduction from baseline on the vertical axis against daily Pregabalin dose in milligrams on the horizontal axis. The graph compares results from different studies with dose regimens labeled as Study E1 BID, Study E2 TID, Study E3 BID, and Study E3 TID, each represented with distinct markers and showing statistically significant p-values at various dose levels.*

FDA Label Image

Pregabalinfigure8 (Pregabalinfigure8)

A bar chart depicting responder rates (%) for Pregabalin at different doses compared to placebo. The chart compares placebo (22.6%), 2.5 mg/kg/day (29.1%), and 10 mg/kg/day (40.6%), with the number of subjects for each group noted below the bars (Placebo: 93, 2.5 mg/kg/day: 103, 10 mg/kg/day: 96). The y-axis represents responder rate percentage, and the x-axis shows treatment groups.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo. The y-axis shows percent of patients improved from 0 to 100%, and the x-axis shows percent improvement in pain from baseline from 0 to 100%. Four distinct lines represent the data for each treatment group across the pain improvement range.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure of Pregabalin, depicting its molecular arrangement with an amino group, methyl substitution, and carboxylic acid functional group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.